A new study validates Low-Pass Genome Sequencing (LP GS) as a robust and cost-effective alternative to Chromosomal Microarray Analysis (CMA) for prenatal diagnosis. LP GS detects six additional Copy Number Variations (CNVs) in cases with negative CMA results, highlighting the importance of sequencing depth in its detection sensitivity.
A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.
Scientists developed a same-day test to identify abnormal fetal chromosomes using prenatal tests and tissue from miscarriage or biopsies. The STORK test shows promise in diagnosing genetic causes of miscarriage and streamlining IVF, potentially saving time and cost.
A new benchtop semiconductor sequencing procedure and bioinformatics software tools can detect multiple types of chromosomal abnormalities with high sensitivity and specificity. The noninvasive method uses cell-free fetal DNA and is faster, cheaper, and safer than current procedures.
A new genetic test using microarray analysis has been shown to detect clinically relevant information more effectively than the current standard method of prenatal testing. Microarray also identified additional abnormalities not detected by karyotyping in cases with advanced maternal age or positive screening results.
A nationwide study has found that chromosomal microarray testing detects additional genetic abnormalities in about 1 in 70 normal karyotype samples and 6% of cases with structural abnormalities. The new test may soon replace standard karyotyping for prenatal testing, providing more information on potential disorders.